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Background: Limited evidence exists on the effectiveness of external diabetes support provided by diabetes
specialists and community retail pharmacists to facilitate insulin-prescribing in family practice.
Methods: A stratified, parallel group, randomized control study was conducted in 15 sites across Canada. Family
physicians received insulin initiation/titration education, a physician-specific ‘report card’ on the characteristics of
their type 2 diabetes (T2DM) population, and a registry of insulin-eligible patients at a workshop. Intervention
physicians in addition received: (1) diabetes specialist/educator consultation support (active diabetes specialist/
educator consultation support for 2 months [the educator initiated contact every 2 weeks] and passive consultation
support for 10 months [family physician initiated as needed]); and (2) community retail pharmacist support (option
to refer patients to the pharmacist(s) for a 1-hour insulin-initiation session). The primary outcome was the insulin
prescribing rate (IPR) per physician defined as the number of insulin starts of insulin-eligible patients during the
12-month strategy.
Results: Consenting, eligible physicians (n = 151) participated with 15 specialist sites and 107 community
pharmacists providing the intervention. Most physicians were male (74%), and had an average of 81 patients with
T2DM. Few (9%) routinely initiated patients on insulin. Physicians were randomly allocated to usual care (n = 78) or
the intervention (n = 73). Intervention physicians had a mean (SE) IPR of 2.28 (0.27) compared to 2.29 (0.25) for
control physicians, with an estimated adjusted RR (95% CI) of 0.99 (0.80 to 1.24), p = 0.96.
Conclusions: An insulin support program utilizing diabetes experts and community retail pharmacists to enhance
insulin prescribing in family practice was not successful. Too few physicians are appropriately intensifying diabetes
management through insulin initiation, and aggressive therapeutic treatment is lacking.
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The majority of patients with type 2 diabetes mellitus
(T2DM) are managed in the family practice setting [1],
but approximately 50% of these patients do not meet
guideline-recommended glycemic targets [2,3]. Clinical
practice guidelines emphasize insulin therapy for T2DM
as an appropriate therapy at any point when glycemic
targets are not met [4,5]. Recent studies of primary care
physicians in Canada have found that only 12% [2] to
15% [3] of patients with T2DM were prescribed insulin
(with or without oral agents) while the literature suggests
suggest that up to 60% of patients may eventually require
insulin therapy [6]. These data indicate that family
physicians remain uncomfortable initiating and managing
insulin for their patients. Indeed, in a survey on patient
and healthcare provider attitudes towards insulin, most
nurses and general practitioners (50-55%) reported that
they delay insulin treatment until absolutely necessary [7].
Physician, patient, and contextual factors interact to
influence physician prescribing behaviors [8-11]. Phys-
ician -level barriers include: lack of knowledge and clin-
ical skills for diabetes management [8]; time constraints
[12,13]; ineffective charting systems [13-15]; clinical in-
ertia [16,17]; and absence of organizational systems that
allow adequate time and resources. In addition, physicians
resist prescription of insulin due to concerns about patient
weight gain, hypoglycemia, and patient expectations and
fears, including injection anxiety.
The delivery of primary healthcare services is in transi-
tion in Canada. A key feature of this reform is the inclusion
of pharmacists and other interdisciplinary allied health
professionals within family healthcare teams [18-21]. The
pharmacy profession is also experiencing rapid change in
the Canadian healthcare system. Transition in scope of
practise to include limited prescribing rights has occurred
or has been proposed in a number of Canadian provinces
[22-24] following other international jurisdictions [25].
Furthermore, in Canada, pharmacists constitute the fastest
growing group of certified diabetes educators [26]. Direct
integration of pharmacists into a family practice setting
has been shown to positively affect physician-pharmacist
collaboration and patient outcomes [27-30], however the
effectiveness of support provided by community retail
pharmacists on patient medical outcomes is inconclusive
[31-33].
The objective of the Advancing Insulin Management
in General Practice (AIM@GP) trial was to determine
the effectiveness of an insulin initiation strategy utilizing
diabetes specialist and community retail pharmacy sup-
port to increase family physician insulin prescribing
rates. The strategy targeted recognized major barriers to
physician insulin prescribing: time constraints; system
support; and clinical inertia. Providing access to a dia-
betes expert had the potential to act as a remindersystem and maintain knowledge gained from a work-
shop. Providing access to a community retail pharmacist
had the potential to be time-saving and an alternative
organizational system for the insulin initiation process.Methods
A stratified, parallel group, randomized controlled study
was conducted in family physician clinics and commu-
nity pharmacies across Canada from July 2006 to April
2010. The University of Western Ontario Centre for
Studies in Family Medicine served as the Coordinating
Centre. Ethics approval was obtained from academic
ethics committees across Canada including The Univer-
sity of Western Ontario.
Family physician enrollment occurred from July 2006
to September 2008. Physicians invited to participate
were randomly selected from a published national direc-
tory [34]. Physicians provided written, informed consent,
and were screened for eligibility and included: full time
status [>25 hours/week]; ability to generate a list of
patients with T2DM [ICD-9, 250 billing code]; minimum
of 35 patients with T2DM, 4 insulin-eligible patients in
the practice; and attendance at a mandatory workshop.
Physician study exclusion criteria included: academic prac-
tice; participation in a diabetes behaviour-change interven-
tion trial; planned retirement or moving practice to
another city; or planned extended locum coverage
beyond 4 weeks during the subsequent 12 month inter-
vention period. Enrollment ended when all physicians
assessed for eligibility consented, refused consent, or were
deemed unable to follow-up (i.e. moved).
Community pharmacist recruitment was conducted
utilizing a national registry at the Department of Family
Medicine at McMaster University. Potential pharmacists
in geographic proximity to the postal codes of con-
senting physicians were identified and surveyed to deter-
mine their diabetes education training and pharmacy
services and resources.
Physicians generated a list of all patients with T2DM
in their practice and mailed study information to all.
Study auditors reviewed the charts of patients who
provided written informed consent and collected year of
birth, year of T2DM diagnosis, glycosylated haemoglobin
(HbA1c) values and glucose-lowering medications. The
remaining charts of patients who either, did not consent
or did not respond, were reviewed by the physician to
determine insulin-eligibility. Patients were considered
insulin-eligible if they had an HbA1c ≥7.5% (most recent
laboratory value) and their oral anti-diabetes drug
(OAD) score was ≥1.5 (OAD score is the sum of all
OADs prescribed; OAD ½ to maximum dose = 1 OAD)
[35]. LantusW or NPH insulin was available free of
charge for 6 months to all insulin-eligible patients.
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graphic site and their level of comfort prescribing insulin
(determined by questionnaire) and randomly allocated
(1:1) in a blocked manner to an insulin initiation strategy
(intervention) or usual care (control) by the Coordinat-
ing Center. Sanofi-aventis generated the mechanism
used to implement the random allocation sequence. A
follow-up chart audit commenced 15 months post work-
shop (defined for each physician; January 2007 – March
2010).
Study sites hosted insulin initiation workshops for all
physicians enrolled in the study to ensure comparable
knowledge on the appropriate use of insulin therapy in
T2DM. All physicians received a complete registry of
insulin-eligible patients in their practice. Pharmacists
attended the same program but were educated separately
to avoid contamination. The workshop focussed on educa-
tion regarding glycemic control, the rationale for insulin
prescription, and common patient barriers. Additional
activities included viewing of an insulin initiation video
and hands-on experience with an insulin pen. For
physicians, summary chart audit data were presented and
individual practice-specific ‘report cards’ distributed.
Physicians were notified of their randomization status at
the workshop by the Coordinating Center. Intervention
physicians had the opportunity to meet pharmacist(s) with
whom they were matched.
Intervention – insulin initiation strategy
Physicians randomized to the intervention group were
provided with a 12-month insulin initiation strategy
consisting of (1) diabetes specialist/educator consult-
ation support (active diabetes specialist/educator con-
sultation support for 2 months [the educator initiated
contact every 2 weeks] and passive consultation support
for 10 months [family physician initiated as needed]);
and (2) community retail pharmacist support (option to
refer patients to the pharmacist(s) for a 1-hour insulin-
initiation session). The session checklist included educa-
tion on insulin action, injection sites, the pen device,
and hypoglycemia awareness and treatment.
Primary outcome
The primary outcome was the physician’s insulin pre-
scribing rate (IPR)—the number of insulin starts per the
12-month intervention of insulin-eligible patients.
Secondary outcomes
Secondary clinical outcome measures, limited to the
data from the audit of consenting patients’ charts,
included: HbA1c; fasting plasma glucose (FPG); OAD
prescription and score; insulin prescription and dosage;
proportion of patients at HbA1c target (≤7.0%); and pro-
portion of patients with intensification of diabetesmanagement (i.e. increased dose of OAD or insulin,
increased OAD score, or the addition of insulin). For
those patients prescribed insulin during the intervention,
additional outcomes included: number of days from
study start to insulin initiation; the change of HbA1c,
FPG, and OAD score; and type(s) of insulin prescribed
from initiation of insulin to 3 and 6 months post-
initiation.
The physician knowledge, attitude and self-efficacy
questionnaire was used to create change scores (pre –
post intervention) to measure physician knowledge, atti-
tude and self-efficacy [36,37] for both glycemia control
and insulin initiation and titration. This questionnaire
was developed by the Coordinating Centre for this pro-
ject and tested for content validity (example questions
are provided in Table 1).
Sample size calculation
With a standard deviation of 7.1 estimated from Poisson re-
gression, two-sided alpha of 0.05 and power of 0.90, the
sample size required was 89 physicians per group (n = 178).
Protocol modifications due to recruitment challenges in-
cluded inclusion of group practice physicians (excluded in
original protocol), and reduction of the minimum required
number of patients with T2DM (original protocol = 50) and
insulin-eligible patients (original protocol = 8).
Analysis
The unit of analysis was the physician. Intention-To-Treat
analysis was performed on the primary outcome with the
IPR imputed as zero if data were not available. The
analyses of secondary outcomes were based on all avail-
able data. A p value of ≤ 0.05 was deemed statistically
significant. Analyses were generated using SAS Version
9.1. All data were examined and the appropriate analyses
were employed.
Primary outcome
The IPR was analyzed using Poisson regression with
intervention group as a class effect and mean HbA1c at
baseline as a covariate from which the mean number of
people started on insulin per 12 months, standard error
(SE) and 95% confidence intervals (CIs) were calculated.
Secondary outcomes
Continuous variable changes from workshop to 15 -
months post-workshop were examined using analysis of
covariance (ANCOVA) with the intervention group,
baseline mean HbA1c, insulin comfort stratum and
pooled site as class effects, and corresponding baseline
value of the variable of interest as a covariate.
ANOVA procedures were used to compare intervention
and control baseline physician and practice demographics
for continuous variables and chi-square tests for categorical
Table 1 Example questions from the knowledge attitude and self-efficacy questionnaire
Questionnaire section Example questions / Statements
Attitude There is little point in trying to achieve optimal glucose because complications from
diabetes are inevitable
5 point Likert Scale
(Strongly Agree to Strongly Disagree)
Diabetes is harder to treat than other chronic diseases
I will not prescribe insulin because I believe it is too complicated to initiate
Self-Efficacy How confident are you to give adequate support and clear directions to patients on how to
manage diabetes
5 point Likert Scale
(Not at All to Completely)
How confident are you to prescribe and titrate insulin when a patient is anxious and is
resists initiating insulin therapy
Knowledge Diabetes related complications for both Type 1 and Type 2 could be prevented through
optimal glucose control
Multiple Choice & True/False Insulin replacement therapy with type 2 diabetes may be required for most patients during
the duration of their disease.
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scores were analyzed using one-way ANOVA.
Results and discussion
Results
Of 443 family physicians who consented for screening,
154 were randomized and 151 were included in the final
analysis (n = 73 in the intervention group, n = 78 in the
control group). Three physicians withdrew prior to
attending the workshop, all were blind to which group
they were allocated. An additional 6 physicians withdrewAssessed for eligibility 
(n=3935)




Did not receive 
allocated intervention 



























Consented for Screening (n=44
Randomized (n=154)
Figure 1 CONSORT diagram - disposition of physician subjects.after attending the workshop, prior to the final chart
audit. Data were collected from 11,380 patient charts.
See Figure 1 for the disposition of physician subjects and
patient consent distribution. Fifteen specialist sites and
107 community retail pharmacists were available to the
intervention group physicians.
Table 2 outlines baseline demographics of physicians
and practice characteristics by study group. Physicians
were comparable in their demographics with the exception
that intervention physicians were older (p = 0.03), reported
seeing significantly more patients per day (p = 0.02), hadExcluded (n=289)
Not meeting inclusion criteria 
(n=49 ineligible by questionnaire; 
n=45 <35 T2DM patients; n=18 
<4 insulin-eligible patients)
Withdraw after consent (n=148)
Refused to participate (n=29)




Did not receive 
allocated intervention 









Consent refusal (n = 3253)
Cannot follow-up, ie. moved 
(n=239)
3)
Table 2 Baseline demographic characteristics of physicians (n = 151)
Physicians Intervention Control p value*
n = 73 n = 78
Mean age in years (SD) 51.4 (8.81) 48.2 (9.06) 0.03
Male (n,%) 53 (72.6) 59 (75.6) 0.67
Urban (n,%) 56 (76.7) 61 (78.2) 0.83
Mean years in practice (SD) 26.1 (8.79) 23.1 (9.55) 0.05
No DM CME** Attendance (n,%) 21 (38.2) 7 (11.1) < 0.01
Mean number of patients per physician (SD) 2440 (1239) 2365 (1206) 0.72
Mean number of patients seen per day per physician (SD) 39.6 (13.15) 35.0 (8.95) 0.02
Mean number of patients with T2DM per physician (SD) 82.1 (38.57) 80.6 (36.30) 0.81
Did not routinely initiate insulin (n,%) 68 (93.2) 69 (88.5) 0.32
*One way ANOVA or chi-square test.
**CME – diabetes related continuing medical education.
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level of diabetes-related Continuing Medical Education at-
tendance (p < 0.01) than control physicians. IPR subgroup
analyses to account for differences in baseline demograph-
ics showed no significant impact on the primary outcome
and therefore these were not controlled for in any subse-
quent analyses.
Patient summary data (Table 3) were computed for
consenting patients (49.6% consent rate) and were com-
parable between study groups. Overall glycemic control,
as measured by mean HbA1c, was excellent in both
study groups, 7.11% and 7.19% for consenting patients
in the intervention and control groups, respectively.
Primary outcome
Intervention physicians had a mean (SE) IPR of 2.28
(0.27) compared with 2.29 (0.25) for the control phy-
sicians, with an estimated adjusted RR (95% CI) of 0.99
(0.80 to 1.24), p = 0.96. No significant differences were
found between the two groups.Table 3 Patient summary statistics
All Patients* (n)
Consenting Patients** (n)
Mean HbA1c at baseline (SD)**
Mean years since T2DM diagnosis (SD)**
Mean number of insulin-eligible patients at time of workshop per physician (
Mean HbA1c of insulin-eligible patients at time of workshop (SD)**
Mean number of patients newly prescribed insulin between Workshop and
12 months post (SD)**
Mean number of office visits during study for insulin-eligible patients at the t
of insulin initiation (SD)
Mean elapsed time in days, workshop to first office visit for insulin-eligible pa
at the time of insulin initiation (SD)
*All patients with T2DM in practice.
**Data from consenting patients’ charts only.Secondary outcomes
Statistically significant within-group differences for both
intervention and control physicians revealed a higher
percentage of patients prescribed OADs, OAD score,
and increased percentage of patients prescribed insulin
at 15 months (p < 0.05). Intervention physicians signifi-
cantly increased the insulin daily dose (p < 0.01) by
15 months (Table 4). Secondary analyses of between-
group differences of consenting patient charts showed an
increase at 15 months in the mean daily dose of insulin
prescribed by intervention physicians, with an adjusted
mean (SE) of 5.96 (2.83), 95% CI (0.35 to 11.56), p = 0.04.
No other treatment effects between intervention and
control groups were evident (Table 4).
Analyses of patients insulin-eligible at the time of in-
sulin initiation found no significant treatment effects be-
tween intervention and control group physicians at 3 or
6 months post insulin initiation; however within-group
reductions (p < 0.05) were found across both groups for
HbA1c, FPG and OAD score at 3 and 6 months postIntervention Control p value
5560 5820
2858 2788
7.11 (0.43) 7.19 (0.52) 0.32
7.9 (2.54) 8.0 (2.90) 0.80
n,%) 10.9 (5.80) 11.3 (7.09) 0.70
8.6 (0.59) 8.6 (0.76) 0.74
1.8 (1.87) 1.9 (1.71) 0.91
ime 6.0 (2.24) 5.9 (2.39) 0.84
tients 45.3 (32.92) 65.4 (53.99) 0.04
Table 4 Within and between-group change from workshop to end of study (15 months)
Group Descriptive statistics Mean (SD) Change at 15 months:
Within-group p-value





HbA1c*,% I (n = 73) 7.12 (0.42) 7.09 (0.41) 0.34 0.02 (0.04) (−0.05 to 0.09) 0.63
C (n = 76) 7.20 (0.52) 7.15 (0.51) 0.13
% patients HbA1c≤ 7.0% I (n = 73) 58.40 (16.20) 58.68 (15.40) 0.76 −1.22 (1.30) (−3.78 to 1.35) 0.35
C (n = 76) 55.95 (15.65) 57.58 (16.12) 0.15
FPG† level in mmol/L I (n = 71) 7.86 (0.67) 7.78 (0.68) 0.13 0.01 (0.07) (−0.13 to 0.15) 0.85
C (n = 70) 7.89 (0.69) 7.82 (0.68) 0.22
% patients prescribed OAD‡ I (n = 73) 80.87 (10.83) 83.32 (9.98) < 0.001 0.87 (0.65) (−0.42 to 2.16) 0.18
C (n = 76) 79.24 (12.06) 81.12 (11.14) < 0.001
OAD score§ I (n = 73) 1.32 (0.20) 1.37 (0.21) < 0.001 0.01 (0.02) (−0.03 to 0.04) 0.65
C (n = 76) 1.38 (0.21) 1.41 (0.24) 0.02
% patients prescribed insulin I (n = 73) 11.53 (8.93) 17.14 (10.64) < 0.001 −1.06 (0.88) (−2.80 to 0.69) 0.23
C (n = 76) 11.53 (8.51) 18.38 (10.82) < 0.001
Insulin daily dose (units) I (n = 61) 47.91 (21.24) 53.64 (22.71) < 0.01 5.96 (2.83) (0.35 to 11.56) 0.04
C (n = 57) 57.19 (26.21) 54.94 (23.65) 0.30
Intensification of diabetes
management**
I (n = 73) – 31.59 (14.17) – −0.29 (2.35) (−4.93 to 4.34) 0.90
C (n = 76) – 32.80 (14.91) –
Note: CI = confidence interval, ANCOVA = analysis of covariance with treatment, stratum, and pooled site effects and the corresponding baseline value as covariate
used for the change from baseline (difference: endpoint-baseline) with p-values based on actual data.
*HbA1c – glycosylated hemoglobin.
†FPG – fasting plasma glucose.
‡OAD – oral anti-diabetes drug.
§OAD score = sum of all OADs prescribed; OAD ½ to maximum dose = 1 OAD.
¶These are between-group results where change from workshop to 15 months was compared between intervention and control groups using ANCOVA, treatment
effect is adjusted for baseline effect and pooled site effect.
**Intensification of diabetes management – Increased dose of OAD or insulin, increased OAD score, or the addition of insulin; Intensification is a one-time post
workshop variable, therefore no within group differences.
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shop to first office visit for patients insulin-eligible at the
time of insulin initiation was significantly lower for in-
tervention physicians (45.3 days, SD = 32.92), compared
with control physicians (65.4 days, SD = 53.99), p = 0.04
(Table 3).
At 15 months, the change in physician’s knowledge, at-
titude and self-efficacy of glycemia control and insulin
initiation and titration did not differ between study
groups. Statistically significant within-group differences at
15 months showed increased knowledge, attitude and self-
efficacy of insulin initiation and titration for both groups.
Intervention and control physicians also displayed increased
self-efficacy of glycemic control, p < 0.01. Increased know-
ledge of glycemia control was limited to intervention
physicians, p < 0.01.
Discussion
Offering family physicians the option to utilize commu-
nity retail pharmacists for insulin initiation with back-up
support by a specialist team did not result in a signifi-
cant improvement in insulin prescribing behaviour. This
trial, therefore, provides no evidence to support a changein strategy for initiating insulin therapy in T2DM in
family practice by providing an external expert support
structure.
These findings are supported by previous literature
showing lack of improvement in patient outcomes by
interventions involving community retail pharmacists
[32,33,38]. Pharmacists are highly qualified professionals
with a strong interest in diabetes care. Thus there is a
need to develop and evaluate how to optimize their in-
clusion in collaborative diabetes care. A better use of
healthcare resources with improved clinical outcomes
could come from supporting the direct integration of
pharmacists into the family practice setting, an organisa-
tional structure supported in the literature [30,39,40].
There are several possible factors that may have
contributed to the lack of effect of the intervention. The
number of insulin-eligible patients for both intervention
and control groups was lower than anticipated, limiting
the total number of patients for physicians to act upon.
There may also have been minimal pressure for physicians
to act on the insulin-eligible patients who were only mod-
erately out of target (i.e. with an HbA1c ≥7.5%). Clinical
practice guidelines recommend aggressive treatment of
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study examining clinical inertia in patients with T2DM
revealed a high mean HbA1c of 9.5% at the time of insulin
initiation [41]. Regardless of the sufficiently high risk
HbA1c, physicians often pursue other glycemia-lowering
options before turning to insulin [7]. A recent Canadian
study of family physicians in practice for less than ten
years demonstrated a greater willingness to share clinical
information and communicate with pharmacists com-
pared to more established family physicians [42]. The
physicians in this study were older and had been in prac-
tice a mean duration of 26 and 23 years and thus may
have had more difficulty adopting the intervention. The
significant improvement of physicians’ knowledge, attitude
and self-efficacy of insulin initiation and titration de-
monstrates the strength of the workshop for both groups
and may potentially have impacted on the differences be-
tween groups. Clinical inertia, the lack of clinical action
when one has the knowledge and opportunity [16], was
however still evident in both groups with a lower than
expected rate of insulin initiation in patients identified as
being insulin-eligible in their practices.
Limitations
Participation bias may have led to the inclusion of
physicians with a more active interest in insulin initi-
ation. However the randomized controlled design
ensured that participation bias occurred in both groups.
The estimated sample size of 89 physicians per group
was not achieved hence the final results may have been
underpowered. However, as the means were exactly the
same, it was unlikely that even with sufficient power that
a difference would have been detected. Risk of contam-
ination of the control physicians could have occurred if
they practiced in the same location as an intervention
physician. However, this situation occurred for only 3
control physicians thus we do not believe it affected the
overall results. In addition, diabetes specialists and
pharmacists did not provide support to the control
physicians in the study. The “Hawthorne” effect, which
suggests that physicians in a research study may be
influenced by the belief that they are being monitored
and change their behaviour accordingly [43] may have
also had an effect, thus making it difficult to detect a
statistically significant difference. Lastly, pharmacist re-
cruitment challenges delayed the start of the intervention
for some physicians, perhaps impacting the intervention
and potential outcomes.
Conclusion
The approach of pairing family physicians with diabetes
experts and community retail pharmacists as a facilitating
infrastructure to enhance insulin prescribing behaviour
in family practice was not successful. Too few familyphysicians are appropriately intensifying glycemia man-
agement through insulin initiation, and aggressive thera-
peutic treatment is lacking. Primary care reform models
promoting the interdisciplinary support of healthcare
teams for chronic disease management including integrat-
ing pharmacists into the family practice setting, a strategy
that has been shown to positively affect outcomes, may
constitute a better use of healthcare resources.
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